Cannabis for Alzheimer's Disease
Gooey Rabinski
Founder at Higher Learning LV and technical writer and instructional developer
"I love your articles. Informative, rich, clean. Amazing work." — Miriam Sanger, cannabis journalist, Ra'ananna, Central, Israel, August 2020
"If you aren’t following Curt Robbins, you are missing out on one of the smartest people in cannabis." — Cannabis & Tech Today Magazine, 2020
"Curt Robbins from California is an encyclopedia of cannabis knowledge." — Ian Jessop, Cannabis Health Radio, 2017
Discovered in 1906 by Dr. Alois (Aloysius) Alzheimer, a German psychiatrist and neuropathologist, Alzheimer’s disease is the sixth leading cause of death in the United States. Alzheimer stumbled upon the ailment when performing an autopsy on the brain of a woman who died of a then-unknown mental illness.
Surprisingly, Alzheimer’s disease begins damaging the brain up to a decade prior to the onset of any form of short-term memory loss—the stereotypical first discernable symptom of the disease that leads to a positive diagnosis.
Alzheimer’s disease is a progressive neurodegenerative brain disorder and the most common form of dementia (it composes 60-70 percent of all cases of dementia). About five million Americans have Alzheimer’s disease. One in three senior citizens will die from the condition or another form of dementia (such as Parkinson’s disease).
Research Studies
A 2020 study entitled “The Implications of Late-life Cannabis Use on Brain Health: A Mapping Review for Future Research” that was published in the journal Ageing Research Reviews investigated the effects of cannabis use by seniors.
- To continue reading this article, visit Higher Learning LV.
About The Author
Curt Robbins is a technical writer, instructional designer, and lecturer who has been developing science-based educational and training content for Fortune 200 enterprises for more than 30 years. His clients have included Federal Express, Microsoft, Sun Microsystems, Northrop Grumman, National City Bank, Strainprint Technologies Ltd., the J.M. Smucker Company, and USAA.
Robbins has developed more than 600 educational articles regarding hemp and its various health components, including terpenes, cannabinoids, and the human endocannabinoid system for clients in the U.S., Canada, and Israel. His latest white paper, CBG: The Mother of Cannabinoids, is an evidence-based 50-page deep dive into the biochemistry of the hemp-derived phytocannabinoid cannabigerol that features 60 peer-reviewed research study citations.
Robbins currently serves as Director of Curriculum Development for Higher Learning LV™ based in Las Vegas, Nevada. Robbins can be found on Twitter at @RobbinsGroupLLC and via email at curtarobbins@gmail.com. To learn more, search for his social media hashtag campaigns on your favorite social media network:
- #LearnAndTeachOthers™
- #TeachYourselfTerpenes™
Very promising treatment. I wish this was an option before Alzheimer's consumed my mother. This is why we need to promote more research and adoption.
Accomplished Entrepreneur
3yI began my Mother on a regimen of cannabis nearly 3 years ago. She was diagnosed with Alzheimer’s in the summer of 2017, when asked where she lived, she said Philadelphia. She has lived in New York her entire life. She couldn’t draw a simple circle and forgot what day, year and month it was. Because of her chronic pain, we decided it was time to try medicinal marijuana. Not only has it helped better than any opioid, but she is speaking in full sentences, follows politics and has pretty healthy debates with others. I cannot express enough my gratitude for cannabis, it has given my Mother a new lease on life, and I have my Mom back. 🙏💜
Holistic Cannabis Practitioner at Jannabis Wellness, Author, Program Director, Cannabinoid Medical Sciences, John Patrick University School of Integrative and Functional Medicine
3yThanks for this very comprehensive review of cannabinoids and Alzheimer's.